SCHEMBL30765745

SCHEMBL30765745

CC(C)[C@@H](Nc1cnc(-c2ccccc2F)n(CC(=O)O)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 4/20 0.37
EGLN1 Q9GZT9 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
MMP12 P39900 2/20 0.34
MMP13 P45452 2/20 0.34
LMNA P02545 2/20 0.34
PTGDR2 Q9Y5Y4 2/20 0.34
CYP2C9 P11712 1/20 0.34
PTGDR Q13258 1/20 0.34
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30766151 0.92 ELANE (0.37) ELANEEGLN1ALDH1A1HPGDLMNA
SCHEMBL30765722 0.89 ELANE (0.35) ELANEALDH1A1HPGDLMNAGABRP
SCHEMBL31558526 0.88 LMNA (0.34) ELANEEGLN1ALDH1A1HPGDLMNA
SCHEMBL30765662 0.88 LMNA (0.34) ELANEEGLN1ALDH1A1HPGDLMNA
SCHEMBL30765536 0.88 LMNA (0.34) ELANEALDH1A1HPGDLMNAGABRP
SCHEMBL30765534 0.87 GAA (0.40) ELANEALDH1A1HPGDLMNAGABRP
SCHEMBL31558470 0.87 LMNA (0.37) ELANEALDH1A1HPGDLMNAPTGDR2
SCHEMBL30765981 0.87 LMNA (0.37) ELANEALDH1A1HPGDLMNAPTGDR2
SCHEMBL30765454 0.85 ELANE (0.37) ELANEPTGDR2CYP2C9PTGDRHDAC6
SCHEMBL31558409 0.83 POLB (0.36) ELANEALDH1A1MMP12MMP13LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed